Marinus Pharmaceuticals Inc at 38th Annual J.P Morgan Healthcare Conference Transcript
Good morning, everyone. Thanks for coming. My name is Rumen Vasilev, and I'm a member of the JPMorgan team. It is my pleasure to introduce the CEO of Marinus, Scott Braunstein.
Well, good morning, and thank you all for coming. It's Thursday. I know it's been a long week for many of us. It's raining outside, so thrilled to have you here today. And I'm going to jump right in because we have quite a bit of material to cover.
That's our forward-looking statement, and you can find that on our website.
And let me start by telling you a little bit about our company, Marinus Pharmaceuticals. We have been studying ganaxolone, a GABA modulator, for many years. But since taking over the company a little less than a year ago as executive chairman and now CEO, we are focusing our efforts in the epilepsy space. We are fortunate enough to have several formulations of ganaxolone, both IV and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
